Sonnet BioTherapeutics

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sonnet BioTherapeutics Holdings, Inc. is a clinical stage biotechnology company, which engages in the innovation of biologic medicines. Its Fully Human Albumin Binding (FHAB) technology utilizes a single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its pipeline focuses on cytokines, a class of cell signaling peptides that, among other important functions, serve as potent immunomodulatory agents. The company was founded by Pankaj Mohan and John K. Cini in 2011 and is headquartered in Princeton, NJ.

Additional data presented from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors. Cytokine data reveal extended PK profile for SON-1010: Induces prolonged and controlled IFNγ response No evidence of cytokine release syndrome Clinical benefit was seen in 36% of patients (5/14) with advanced solid tumors Entered into a collaboration with Roche for the clinical evaluation of SON-1010 with atezolizumab (Tecentriq®) in ovarian cancer with study initiation currently underway Announced data from two IND-enabling toxicology studies with SON-1210 in non-human primates Doses were well tolerated at over 50 times the anticipated human dose Successfully completed a $15.0 million underwritten public offering PRINCETON, NJ / ACCESSWIRE / May 10, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months and six months ended March 31, 2023 and provided a business update.

Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update

PRINCETON, NJ / ACCESSWIRE / April 18, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing has been formally reviewed in both of the current Phase 1 clinical trials, and the Company is now enrolling the final dose cohort in the cancer trial. SON-1010 is a proprietary version of human interleukin-12 (IL-12), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform.

Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting

PRINCETON, NJ / ACCESSWIRE / April 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) on Tuesday, April 18, 2023 at 5:00 pm ET. Webcast presenters will include: Richard Kenney, M.D.

Sonnet BioTherapeutics Announces Webcast to Discuss Clinical Data from the SB101 Study with SON-1010 Being Presented at the AACR 2023 Annual Meeting

PRINCETON, NJ / ACCESSWIRE / March 14, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that data from the company-sponsored SB101 multiple-dose clinical trial (NCT05352750) of SON-1010 (IL12-FHAB) in adult patients with advanced solid tumors will be presented in a poster session at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, to be held April 14-19, in Orlando, Florida. Presentation details: Title: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics Session Title: Phase I and First-in-Human Clinical Trials in Progress Presentation Type: Poster Session Date and Time: Tuesday April 18, 2023, 1:30 PM - 5:00 PM Abstract Number: CT245 Location: Poster Section 46 About Sonnet BioTherapeutics Holdings, Inc. Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific, bifunctional action.

Sonnet BioTherapeutics to Present Clinical Data from the SB101 Study with SON-1010 at the AACR 2023 Annual Meeting

Data announced from two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors Entered into collaboration with Janssen Biotech for the evaluation of three Sonnet pipeline compounds Successfully completed two IND-enabling toxicology studies with SON-1210 in non-human primate PRINCETON, NJ / ACCESSWIRE / February 13, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended December 31, 2022 and provided a business update. "This was a productive quarter for Sonnet and one of which we are particularly proud.

Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update

PRINCETON, NJ / ACCESSWIRE / February 8, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a clinical-stage company developing innovative targeted biologic drugs, today announced the pricing of an underwritten public offering of 13,888,888 shares of common stock or common stock equivalents (which includes pre-funded warrants to purchase shares of common stock in lieu of shares of common stock) and investor warrants to purchase up to an aggregate of 27,777,776 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase two shares of common stock at a combined offering price of $1.08, for total gross proceeds of approximately $15.0 million, before underwriting discounts and commissions and offering expenses payable by Sonnet.

Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering

SON-1210 elicited no serious adverse events in repeat, subcutaneous dosing in a GLP toxicology study SON-1210 was well-tolerated using dosing levels at least 50x higher than the highest anticipated human clinical dose level Data show controlled induction of IFNg with no signs of cytokine release syndrome or off-target toxicity PRINCETON, NJ / ACCESSWIRE / February 1, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that two IND-enabling toxicology studies have been completed in non-human primates (NHPs) using its lead bifunctional therapeutic candidate. SON-1210 is a proprietary, bispecific version of human Interleukins 12 (IL-12) and 15 (IL-15), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform.

Sonnet BioTherapeutics Announces Successful Completion of Two IND-Enabling Toxicology Studies with SON-1210 in Non-Human Primates

24 healthy volunteers have been dosed in study SB102 to assess the safety, PK, and PD of SON-1010 without the background of prior chemotherapy PK data shows an extended half-life of SON-1010 of approximately 112 hours, compared to 12 hours for rhIL-12 Simulation of the controlled and prolonged induction of IFNg and minimal related adverse events suggest that dose escalation can continue PRINCETON, NJ / ACCESSWIRE / January 19, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that pharmacokinetic (PK) profile simulation of SON-1010 dosing has been completed in its randomized, placebo-controlled Phase 1 clinical trial in healthy volunteers. Historically, the therapeutic application of cytokines has been limited by relatively short half-lives and off-target toxicities that are typically associated with peak plasma levels.

Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010

Context Therapeutics LLC

Kronos Bio

Ocugen, Inc.

Instil Bio

Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch This Week With Big News

Sonnet's lead product, SON-1010, to be evaluated in combination with Roche's atezolizumab (Tecentriq®) Sonnet will sponsor the clinical study in patients with platinum-resistant ovarian cancer, scheduled to commence during the second calendar quarter of 2023, and Roche will supply atezolizumab PRINCETON, NJ / ACCESSWIRE / January 9, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today a clinical collaboration agreement with Roche. A clinical trial (SB221) will be conducted to assess the safety and preliminary efficacy of SON-1010 (IL12-FHAB) in combination with Roche's atezolizumab in patients with platinum-resistant ovarian cancer (PROC).

Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer

PRINCETON, NJ / ACCESSWIRE / December 15, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the fiscal year ended September 30th, 2022 and provided a business update. Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update

Affimed

Faraday Future Intelligent Electric

Tellurian

Tupperware

Penny stocks to watch this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 To Watch For November 2022

The SB101 and SB102 studies have together dosed 36 subjects to date as dose escalation continues Cytokine data show extended pharmacokinetics of SON-1010 with controlled induction of IFNγ and no signs of cytokine release syndrome All but one patient remain on study, with evidence of tumor improvement at 6 months in one patient PRINCETON, NJ / ACCESSWIRE / November 2, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the safety of SON-1010 dosing in several cohorts has been formally reviewed in both Phase 1 clinical trials and that dose escalation is continuing as early data becomes available. SON-1010 is a proprietary version of human interleukin-12 (IL-12), configured using Sonnet's Fully Human Albumin Binding (FHAB®) platform.

Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010

Akerna Corp

Nokia

Safe-T Group Ltd - ADR

Here's how to find penny stocks on Reddit right now The post Using Reddit to Find Penny Stocks to Buy? Use These Tips  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Using Reddit to Find Penny Stocks to Buy? Use These Tips

PRINCETON, NJ / ACCESSWIRE / November 1, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the company will host a webcast to share initial clinical data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) and its SB102 clinical study with SON-1010 in healthy volunteers (NCT05408572) on Wednesday, November 2, 2022 at 8:30 am ET. Webcast presenters will include:Richard Kenney, M.D.

Sonnet BioTherapeutics Announces Webcast to Discuss Interim Data from the Company's Phase 1 Dose-Escalation Trials of SON-1010 on November 2, 2022

Canopy Growth

1847 Holdings LLC

Tilray Brands

Are these money making tips part of your penny stocks trading strategy? The post How to Take Advantage of Market Volatility With Penny Stocks appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Take Advantage of Market Volatility With Penny Stocks

The award for today's most impressive mover has to go to Sonnet BioTherapeutics (NASDAQ: SONN ). Currently, SONN stock has surged more than 120% on an intraday move that has seen this stock erase more than a month of losses.

Why Is Sonnet BioTherapeutics (SONN) Stock Up 100% Today?

Sonnet's three products, SON-1010, SON-1210 and SON-1410 to be evaluated in combination with Janssen's cell therapy assets In vitro and in vivo evaluations to be conducted by Janssen in preclinical models Subject to successful results, Sonnet could seek an expanded collaboration PRINCETON, NJ / ACCESSWIRE / October 31, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today a collaboration agreement with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, where in vitro and in vivo efficacy of SON-1010 (IL12-FHAB), SON-1210 (IL12-FHAB-IL15) and SON-1410 (IL18-FHAB-IL12) will be evaluated in combination with certain Janssen proprietary cell therapy assets. The agreement was facilitated by Johnson & Johnson Innovation.

Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates

PRINCETON, NJ / ACCESSWIRE / October 4, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet BioTherapeutics"), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on October 3, 2022 informing Sonnet that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on The Nasdaq Capital Market. In order to regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days.

Sonnet BioTherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

The SB101 and SB102 studies have together dosed 19 subjects to date This early review of safety sets the stage for further dose escalation Additional safety and cytokine-specific data are expected during the fourth calendar quarter of 2022 PRINCETON, NJ / ACCESSWIRE / September 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that initial safety has been formally reviewed in both Phase 1 clinical trials of SON-1010(IL12-FHAB) in adults and that dose escalation is continuing. SB101 is a multiple-dose trial for patients with advanced solid tumors that commenced in April (NCT05352750) and has now started treating the third dose cohort.

Sonnet BioTherapeutics Announces Progress in Two Phase 1 Dose-Escalation Trials of SON-1010

A 1-for-14 reverse split of Sonnet BioTherapeutics (SONN) stock has gone into effect. These are the details.

Sonnet BioTherapeutics (SONN) Stock: 1-For-14 Reverse Split Goes Into Effect

PRINCETON, NJ / ACCESSWIRE / September 16, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today that it will effect a 1-for-14 reverse stock split of its outstanding common stock. This will be effective for trading purposes as of the commencement of trading on Monday, September 19, 2022.

Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split

Initiation of two clinical trials of SON-1010 in both healthy volunteers and patients with advanced solid tumors Positive preclinical data of SON-1010 combined with anti-PD1 Checkpoint Inhibition Subsequent Events During The Fiscal Year 2022 Fourth Quarter Initiation of clinical trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy Launch of at-the-market offering of common stock for up to $6.1 million Closing on private placement of preferred stock for $2,250,000 PRINCETON, NJ / ACCESSWIRE / August 15, 2022 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs, announced today its financial results for the three months ended June 30, 2022 and provided a business update. "Sonnet is proud of its progress to date, with two clinical programs in SON-1010 and SON-080 currently advancing in human studies," said Pankaj Mohan, Ph.D.

Sonnet BioTherapeutics Provides Fiscal Year 2022 Third Quarter Business and Earnings Update

Sonnet's first clinical trial with SON-080 is a Phase 1b/2a double-blind, randomized controlled trial This trial is expected to provide safety data compared to previous IL-6 products, along with preliminary efficacy Recruitment initiated with dosing anticipated to begin imminently PRINCETON, NJ / ACCESSWIRE / July 22, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a Phase 1b/2a clinical trial of SON-080 has been authorized to begin. This new study (SB211) will be conducted at multiple sites in Australia in patients with persistent chemotherapy-induced peripheral neuropathy (CIPN).

Sonnet BioTherapeutics Announces Clinical Trial of SON-080 in Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy

Represents Sonnet's second clinical trial with SON-1010 Study expected to provide important PK and PD data for potential additional indications of interest Recruitment initiated with dosing anticipated to begin imminently PRINCETON, NJ / ACCESSWIRE / July 21, 2022 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that a second Phase 1 clinical trial of SON-1010(IL12-FHAB) has been authorized to begin, based on the successful initiation of the first two cohorts in the first-in-human (FIH) dose-escalation trial (SB101) in patients with advanced solid tumors (NCT05352750). This new study (SB102), being conducted in healthy volunteers in Australia, is a single ascending dose-escalation (SAD) trial designed to provide extensive additional pharmacokinetic (PK), pharmacodynamic (PD) and cell response data with SON-1010 (NCT05408572).

News for Sonnet BioTherapeutics Stock (SONN)